These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9566470)

  • 1. A Monte Carlo simulation of advanced HIV disease: application to prevention of CMV infection.
    Paltiel AD; Scharfstein JA; Seage GR; Losina E; Goldie SJ; Weinstein MC; Craven DE; Freedberg KA
    Med Decis Making; 1998; 18(2 Suppl):S93-105. PubMed ID: 9566470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of prophylactic treatment with oral ganciclovir for cytomegalovirus retinitis.
    Moore RD; Chaisson RE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Sep; 16(1):15-21. PubMed ID: 9377120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of cytomegalovirus (CMV) disease prevention in patients with AIDS: oral ganciclovir and CMV polymerase chain reaction testing.
    Rose DN; Sacks HS
    AIDS; 1997 Jun; 11(7):883-7. PubMed ID: 9189213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preevaluation of clinical trial data: the case of preemptive cytomegalovirus therapy in patients with human immunodeficiency virus.
    Paltiel AD; Goldie SJ; Losina E; Weinstein MC; Seage GR; Kimmel AD; Zhang H; Freedberg KA
    Clin Infect Dis; 2001 Mar; 32(5):783-93. PubMed ID: 11229847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The evaluation of cost-effectiveness and cost-utility of valganciclovir for the prophylaxis of cytomegalovirus disease to 200 days after kidney transplantation].
    Kawalec P; Holko P; Szkultecka-Debek M; Paszulewicz A; Boratyńska M; Głyda M; Ignacak E; Maks J; Russel-Szymczyk M; Kaweczyńska-Lasoń A
    Pol Merkur Lekarski; 2013 Jun; 34(204):332-8. PubMed ID: 23882930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged prophylaxis with valganciclovir is cost effective in reducing posttransplant cytomegalovirus disease within the United States.
    Blumberg EA; Hauser IA; Stanisic S; Mueller E; Berenson K; Gahlemann CG; Humar A; Jardine AG
    Transplantation; 2010 Dec; 90(12):1420-6. PubMed ID: 21063245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of treatment administration strategies of ganciclovir for cytomegalovirus retinitis in HIV/AIDS patients in Thailand: a simulation study.
    Teerawattananon K; Iewsakul S; Yenjitr C; Ausayakhun S; Yenjitr W; Mugford M; Teerawattananon Y
    Pharmacoeconomics; 2007; 25(5):413-28. PubMed ID: 17488139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease.
    Liu GG; Hay J
    Pharm Res; 2000 Aug; 17(8):911-9. PubMed ID: 11028934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental cost effectiveness of prophylaxis for cytomegalovirus disease in patients with AIDS.
    Kempen JH; Frick KD; Jabs DA
    Pharmacoeconomics; 2001; 19(12):1199-208. PubMed ID: 11772155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of the efficacy and safety of pre-emptive anti-cytomegalovirus (CMV) therapy in HIV-infected patients with CMV viraemia.
    Mattioni S; Pavie J; Porcher R; Scieux C; Denis B; De Castro N; Simon F; Molina JM
    Int J STD AIDS; 2015 Apr; 26(5):306-12. PubMed ID: 24845948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost of prophylaxis in the management of cytomegalovirus infection in solid organ transplant recipients.
    Oppenheimer F; Gonzalez-Molina M; Rubio M
    Clin Transplant; 2007; 21(4):441-8. PubMed ID: 17645702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
    Bachmann MO
    AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making.
    Annemans L; Moeremans K; Mutimer D; Schneeberger H; Milligan D; Kubin M
    Value Health; 2002; 5(4):347-58. PubMed ID: 12102697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.
    Puttarajappa CM; Hariharan S; Smith KJ
    Clin J Am Soc Nephrol; 2018 Feb; 13(2):290-298. PubMed ID: 29025787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral ganciclovir.
    Schouten JT
    STEP Perspect; 1995; 7(3):1, 11. PubMed ID: 11362979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.
    Luan FL; Kommareddi M; Ojo AO
    Transplantation; 2011 Jan; 91(2):237-44. PubMed ID: 21169881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group.
    Spector SA; McKinley GF; Lalezari JP; Samo T; Andruczk R; Follansbee S; Sparti PD; Havlir DV; Simpson G; Buhles W; Wong R; Stempien M
    N Engl J Med; 1996 Jun; 334(23):1491-7. PubMed ID: 8618603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.